Sign In
Buy TNXP
$12.20
+0.190 (+1.58%)
At Close: Jun 22, 2026
Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)
12:28pm, Tuesday, 19'th Aug 2025
The Tonix Pharmaceuticals Holding Corp. stock price has pulled back so much, and they hold a clear campaign runway for Tonmya into 2026. Despite approval, TNXP shares dropped due to concerns over valu
FDA Approves New Fibromyalgia Drug, Tonix Shares Climb
09:01am, Monday, 18'th Aug 2025
Tonmya is the first FDA-approved fibromyalgia drug in more than 15 years.
Tonix Secures Fibromyalgia Approval - What Investors Should Know
08:45am, Saturday, 16'th Aug 2025
Tonix's Tonmya received FDA approval, marking the first new fibromyalgia therapy in 15 years and driving a post-market stock surge. Despite the approval, I maintain a Hold rating due to Tonix's limite
US FDA approves Tonix Pharma's drug to manage pain related to chronic condition
03:50pm, Friday, 15'th Aug 2025
The U.S. Food and Drug Administration has approved Tonix Pharmaceuticals' drug to manage pain related to a type of chronic condition, the company said on Friday.
Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
04:15pm, Monday, 11'th Aug 2025
FDA PDUFA goal date of August 15 , 2025, for TNX ‑ 102 SL for fibromyalgia: if approved by FDA, TNX ‑ 102 SL would be the first new drug for fibromyalgia in more than 16 years
CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercia
Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025
07:00am, Thursday, 10'th Jul 2025
TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in anima
The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
07:00am, Monday, 07'th Jul 2025
Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox
Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
07:00am, Monday, 30'th Jun 2025
CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be ad
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy
11:30am, Monday, 16'th Jun 2025
I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved mar
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102 SL demonstrat
Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?
07:30am, Friday, 13'th Jun 2025
Tonix Pharmaceuticals' TNX-102 SL shows a high probability of FDA approval for fibromyalgia, supported by positive Phase 3 trials and an acceptable safety profile. A recent $500M shelf offering caused
